Browse Articles

Discover research articles across all indexed journals

Nutrient status alters developmental fates via a switch in mitochondrial homeodynamics

Nature Communications Jie Zhang, Suning Liu, Yang Li et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56528-z

Permanent Electride Magnets Induced by Quasi‐Atomic Non‐Nucleus‐Bound Electrons

Advanced Materials Jeong Yun Hwang, Seung Yong Lee, Kimoon Lee et al. Feb 01, 2025 DOI: 10.1002/adma.202412956

AbstractInterstitial quasi‐atomic electrons (IQEs) in the quantized energy levels of positively charged cavities possess a substantial own magnetic moment and control the magnetism of crystalline electrides depending on the interaction with surrounding cations. However, weak spin‐orbit coupling and gentle exchange interaction restricted by the IQEs preclude a large magnetic anisotropic, remaining a challenge for a hard magnetism. It is reported that 2D [Re2C]2+·2e− electrides (Re = Er, Ho, Dy, and Tb) show the permanent magnetism in a ferrimagnetic ground state, mimicking the ferrites composed of magnetic sublattices with different spin polarizations. Magnetic interaction between Re‐spin lattice and IQE‐spin lattice in the [Re2C]2+·2e− electrides results in a large magnetocrystalline anisotropy and high coercivity, giving a maximum energy product of 15 MGOe. It is demonstrated that the spontaneous breaking of magnetic IQE‐sublattice through substitution with paramagnetic elements produces a crossover into an antiferromagnetic spin ordering of Re‐sublattice, implying that the magnetic sublattice of IQEs drives the permanent magnetism.

A phase IIa clinical trial of first-line cyclical therapy alternating gemcitabine, cisplatin, and durvalumab with pemigatinib for advanced biliary tract cancers with <i>FGFR2</i> -alterations.

Journal of Clinical Oncology Chunjie Li, Michele R. Wing, Julie Reeser et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps645

TPS645 Background: Unresectable biliary tract cancer (BTC) has a poor prognosis. Frontline chemo-immunotherapy (C-IO) for advanced BTC leads to ~25% overall survival (OS) at 24-month, but 93-99% of patients reported adverse events (AEs), and 13-19% of patients stopped treatment drugs due to AEs. FGFR kinase inhibitors (FGFRi) are second-line therapy for 10% of BTC with FGFR2 fusions. However, clinical trials of upfront FGFRi have not accrued well. Cumulative toxicities frequently interrupt treatment and limit feasibility of concurrent C-IO + FGFRi. Over time, side effects from each of therapies have a negative impact on patients’ quality of life (QoL). We previously treated two FGFR2 -altered BTC patients with cyclical chemotherapy (CT) and FGFRi and observed prolonged survival with better QoL. By monitoring serial circulating tumor DNA (ctDNA), we observed development of FGFRi-resistant subclones while on FGFRi and their subsequent clearance after resuming CT. Thus, we have developed a clinical trial to validate our hypothesis that upfront cyclical therapy alternating between C-IO and FGFRi can improve therapeutic efficacy and QoL. Alternating therapy is hypothesized to avoid accumulating toxicities and treat emerging resistance subclones. Methods: In this single-center, single-arm, Phase IIa trial, all treatment-naive patients with FGFR2 -altered advanced BTCs, PS ≤ 1, are eligible. Patients will receive cyclical therapy alternating between two therapy-blocks, starting from C-IO block (2 cycles of gemcitabine, cisplatin and durvalumab, 28-day/cycle), then FGFRi block (3 cycles of pemigatinib on day 1-14 of 21-day/cycle). Block-switch continues until progressive disease (PD), and then we will continue alternated block until the next PD. A sample size of 30 is calculated based on an expected 12-month OS rate of ≥ 55%. The trial is anticipated to enroll the first patient in early 2025. Results: The primary objective is 12-month OS rate. Secondary objectives are overall response rate, progression-free survival, AEs. We will stratify patients to PD-L1 CPS &lt;1 or ≥ 1 to assess if cyclical therapy can enhance IO. Exploratory objectives are (1) assessing dynamics of FGFR2 -ctDNA variants throughout therapy correlating with clinical outcomes, using a custom liquid biopsy (FGFR-Dx) developed at the Ohio State University; (2) assessing QoL scores with EORTC-QLQ-C30 and -BIL21 questionnaires, correlating with clinical outcomes. Results will be compared to historical controls from TOPAZ-1 trial. Conclusions: Cyclical therapy will be one of the first to combine alternating C-IO and targeted therapy in cancer. This strategy can be validated in other tumors if it is proven effective in our trial. Cyclical therapy holds great promise to introduce FGFRi earlier into treatment for BTC and improve both efficacy and QoL.

Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations and overall mortality among adults with colorectal cancer in a multiethnic cohort study.

Journal of Clinical Oncology Edgar Asiimwe, Irina Tolstykh, June M. Chan et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.29

29 Background: High adherence to AICR recommendations on diet, adiposity, and physical activity is associated with improved survival among adults with colorectal cancer (CRC). However, over 80% of participants in existing studies self-reported as non-Hispanic White (NHW). We studied the association between adherence to AICR recommendations and overall mortality among adults with CRC in a multiethnic cohort. Methods: This prospective analysis used data from the Multiethnic Cohort (MEC) study. The MEC is a racially/ ethnically diverse cohort of over 200,000 participants residing in Hawaii and Los Angeles. Lifestyle behaviors in the MEC were assessed by questionnaire at enrolment/Q1 (1993-1996) and periodically over follow-up. We included those with incident CRC before completing Q3 (2003-2008). Follow-up was from Q3 survey completion to December 2019. The main exposure was the standardized AICR score [0-7 points] at Q3. The primary outcome was overall mortality; CRC-specific mortality was secondary. We used multivariable Cox proportional hazards regression to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CIs). Results: There were 1127 adults diagnosed with CRC prior to Q3. Of these, 1079 (95.7%) had non-missing data on the AICR score and comprised our study population. Median (IQR) age at diagnosis was 69 (62-75); median (IQR) follow-up was 12.2 (0.1-16.4) years. There were 489 (45.3%) women. By self-reported race/ethnicity, there were: 153 (14.2%) Black/African Americans, 453 (42.0%) Japanese Americans, 79 (7.3%) Latinos, 165 (15.3%) Native Hawaiians, and 229 (21.2%) NHWs. Only 48 (4.4%) adults had high adherence (AICR≥5 points). Those in the highest category of AICR scores (AICR≥4.5) had statistically significant lower risk of overall mortality relative to those in the lowest category (AICR≤2.5) (HR: 0.64, 95% CI, 0.47-0.89). A similar (but non-statistically significant) association was observed with CRC-specific mortality [HR (high vs low): 0.70, 95% CI, 0.31-1.60]. Those who increased their score between Q1&amp;Q3 had lower overall mortality (HR: 0.87, 95% CI,0.79 - 0.96). Similar trends were observed in stratified analysis by race/ethnicity; however, statistical power was limited. Conclusions: High adherence to AICR recommendations was associated with lower risk of overall mortality in this multiethnic population of adults with CRC. Efforts to increase adherence to AICR recommendations in this population are needed.

Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).

Journal of Clinical Oncology Syvart Dennen, Marty Masek, Paul Cockrum et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.693

693 Background: During 1L treatment of mPDAC with FFX and GnP, hAEs can harm patients (pts) and accrue excess costs to the health system, i.e., costs beyond those of a treated pt without the hAE. This study examined excess total cost of care (TCoC) and components (total inpatient; outpatient transfusion, granulocyte colony-stimulating factor [G-CSF], and thrombopoietic growth factor [TGF]) for three key hAEs (anemia, neutropenia, thrombocytopenia) during 1L FFX, FFX without 5FU bolus (FFXnb), and GnP. Methods: This retrospective observational study utilized Optum Market Clarity claims + EHR linked data. Inclusion criteria were: adult pts diagnosed with mPDAC between 1/1/2015 and 5/31/2023; initiated 1L FFX, FFXnb, or GnP within -14 to +90 days (index date); ≥6 months pre-index enrollment. hAEs during 1L were detected from lab values and grouped all grades combined. Pts were divided into “hAE groups” and “ref. groups” with and without any of the three hAEs of interest, respectively. Pts were matched 1:1 without replacement based on follow-up time. Costs were measured from the day a lab value indicated an hAE until 30 days later and during the corresponding times for ref. pts, then standardized to per-pt-per-month (PPPM). This study did not adjust for differences in pt characteristics. Results: Means and differences (95% CI) in TCoC following hAE detection for each regimen and hAE of interest are presented (Table). PPPM TCoC was greater for all three regimens and hAEs, driven by 1.6–4.9 times higher inpatient costs. Inpatient costs were $5,614 and $5,665 higher for FFX and FFXnb neutropenia pts vs. ref. groups. Use of outpatient G-CSF at any time during 1L was lower for FFX and FFXnb neutropenia pts, at 76% and 63% vs. 83% and 75% in the ref. groups, respectively. Outpatient TGF and transfusions were rare. Conclusions: All hAEs showed excess PPPM TCoC across regimens, driven by inpatient costs. FFX and FFXnb neutropenia pts had lower overall utilization of outpatient G-CSF but higher inpatient costs following detection of neutropenia, which may represent an opportunity for improved pt management. Excess TCoC of hAEs. AE (any grade) FFX, hAE group(N=199, 127, 157) FFX, ref. group(N=199, 127, 157) Diff. (95% CI) FFXnb, hAE group(N=202, 106, 137) FFXnb, ref. group (N=202, 106, 137) Diff. (95% CI) GnP, hAE group (N=406, 268, 270) GnP, ref. group (N=406, 268, 270) Diff. (95% CI) AnemiaTCoC, mean 30,561 22,310 8,251 (4,396–12,106) 31,866 23,380 8,487(4,007–12,966) 32,662 27,697 4,965(1,320–8,610) NeutropeniaTCoC, mean 30,382 24,952 5,430(-31–10,891) 26,588 22,571 4,017(-1,288–9,322) 32,975 31,051 1,924(-4,629–8,477) ThrombocytopeniaTCoC, mean 30,566 22,535 8,031 (3,895–12,166) 31,434 22,958 8,476(2,962–13,991) 33,863 30,751 3,113(-3,310–9,536)

Sustainable synthesis of α-ketoglutaric and methanetriacetic acids from biomass feedstocks

Nature Communications Cheng-Bin Hong, Wangde Hua, Lieke Liu et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56536-z

Emerging 0D Hybrid Metal Halide Luminescent Glasses

Advanced Materials Bohan Li, Yuzhen Wang, Yan Xu et al. Feb 01, 2025 DOI: 10.1002/adma.202415483

Abstract 0D hybrid metal halide (HMH) luminescent glasses have garnered significant attentions for its chemical diversity in optoelectronic applications and it also retains the skeleton connectivity and coordination mode of the crystalline counterparts while exhibiting various physics/chemistry characteristics distinct from the crystalline states. However, understanding of the glass‐forming ability and the specific structural origins underpinning the luminescent properties of 0D HMH glasses remains elusive. In this review, it is started from the solid‐liquid phase transition and thermodynamic analysis of 0D HMHs formed through melt‐quenching, and summarize the current compounds capable of stably forming glassy phases via chemical structural design. The structural characterization methods are further discussed and highlight the exceptional transparency, specific luminescent properties, and glass crystallization behaviors. Moreover, the application prospects demonstrated by these 0D HMH glasses have been presented accordingly in X‐ray detection and imaging, anti‐counterfeiting, and information encryption. Finally, perspective is offered into the future development of this emerging family of 0D HMH glasses and their applications.

Personalized oncogenomic analysis of metastatic squamous cell carcinoma of the anus: Utilizing whole-genome sequencing to guide clinical decision-making.

Journal of Clinical Oncology Renata D'Alpino Peixoto, Melissa McConechy, Howard J. Lim et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.11

11 Background: Metastatic squamous cell carcinoma of the anus (SCCA) is associated with significant morbidity and mortality. Due to its relative rarity, there is limited evidence to support systemic therapy regimens informed by genomic data. This study aims to utilize whole-genome and transcriptome sequencing to enhance the understanding of the genetic alterations driving metastatic SCCA and to identify potentially actionable therapeutic targets. Methods: This report examines nine cases of metastatic SCCA in patients enrolled in the Personalized Oncogenomics (POG) Program at the BC Cancer Agency. Comprehensive genomic profiling, including whole-genome and transcriptome analysis (WGTA) was conducted on fresh tumor biopsy or formalin fixed paraffin embedded (FFPE) tissue. Tumor genomic alterations were analyzed in detail including: SNVs, indels, copy number alterations, structural variants, mutation signatures, viral presence, tumor mutation burden (TMB), expression outliers, and immune cell scores. The somatic alterations were integrated with existing knowledge of drug-target interactions to identify actionable therapeutic targets. Results: Of the nine patients, eight were found to be HPV-positive, with one exhibiting high tumor mutational burden (TMB&gt;10mut/Mb). Mutation signatures included seven cases with AID/APOBEC signatures (commonly seen with HPV), and one case with an ID2 DNA replication slippage signature. The PI3K/AKT/mTOR pathway was the most commonly affected signaling pathway (n=4), followed by FGFR amplification and overexpression (n=3), and RAS/RAF alterations ( BRAF mutation and KRAS overexpression, n=2). EGFR amplification was identified in two cases, one of which also exhibited EGFR overexpression. Additionally, FBXW7 mutations were present in two cases. Immunotherapy was recommended for all nine patients: eight based on HPV positivity, either alone or in combination with other alterations, such as high TMB, SWI/SNF complex alterations, and presence of immune infiltrating cells, and the remaining case based on a SWI/SNF complex mutation. Only two patients ultimately received immunotherapy, both of whom derived clinical benefit. One patient, treated with atezolizumab as part of the phase II CAPTIV-8 trial (NCT04273061), demonstrated progression-free survival (PFS) of 10 months (ongoing), while the other, treated with nivolumab, achieved a PFS of 6 months. Conclusions: Genomic analysis using WGTA supported the recommendation of immunotherapy for all patients in this cohort. Although only two patients received immunotherapy, both experienced clinical benefit, underscoring the potential of personalized genomic-guided treatment in metastatic SCCA.

Clinical and genomic features of the morphological subtypes in advanced pancreatic cancer.

Journal of Clinical Oncology Eugenia Flores-Figueroa, Yuanchang Fang, Maryam Monajemzadeh et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.765

765 Background: In resected pancreatic cancer (PDA), morphology from routine histopathology slides provides a rapid inexpensive biomarker that predicts overall survival and correlates with transcriptomic subtypes. In this study, we evaluated clinical and genomic associations of morphological subtypes in resected and advanced disease and validated the consistency of subtypes in patient-derived organoids (PDO) and mouse xenografts (PDXs) during in vitro and in vivo modeling. Methods: Our cohort included PDA tumor tissues from 152 resectable (stage I/II) and 228 advanced cases (Stage III/IV). Hematoxylin and eosin-stained slides were blindly reviewed by two pathologists and classified into subtypes based on Kalimuthu (1). Morphological subtypes were correlated with clinical and genomic data from whole-genome and transcriptome sequencing. Histological preparations from PDOs and PDXs obtained from pancreatic resections and metastases were reviewed using the same criteria. Results: Morphological subtypes were significantly associated with clinical patterns. Locally advanced PDA exhibited the highest proportion of glandular tumors. Metastatic tumors were enriched for non-glandular morphologies. The non-glandular morphologies were significantly associated with lower survival rates in both resected and advanced tumors. Furthermore, morphological subtypes were significantly associated with unique genomic alterations. Compared to glandular tumors, non-glandular tumors were associated with increased KRAS copy number, KRAS imbalances, and polyploid genomes. In advanced settings, glandular and non-glandular tumors mostly exhibited classical and basal-like transcriptional subtypes, respectively. Squamous tumors had the highest mutation burden and the highest proportion of Basal A signature (2). Using differential gene expression, we identified transcriptional signatures of the morphological subtypes. PDOs and PDXs maintained the morphological subtypes, although non-glandular tumors had a lower success rate for PDO establishment. Conclusions: Morphological subtypes have distinct clinical and genomic associations across all stages of pancreatic cancer, which can be consistently modeled both in vitro and in vivo . These results demonstrate that morphological subtyping offers a rapid and biologically-relevant classification of PDA that could be used for drug development and stratification to predict therapy selection. 1. Gut; 69:317-328 (2020). 2. Nat Gen; 52:231-240 (2020).

p53 pathway genes' mutations as prognostic factors in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center study.

Journal of Clinical Oncology Giovanni Trovato, Diletta Barone, Alexia Spring et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.771

771 Background: Mutations (muts) in oncosuppressor genes have been associated with poor prognosis in different solid tumors. This study aims to evaluate the prognostic impact of p53 pathway muts in mPDAC pts. Methods: For each mPDAC pt enrolled in this study a FFPE tumor tissue specimen was collected and Next Generation Sequencing (NGS) was performed by TSO500HT assay (DNA [523 genes], RNA [55 genes]). Primary endpoint was overall survival (OS). The Kaplan–Meier method was used to estimate efficacy outcome; log-rank test, Peto-Peto test and Cox-regression model were used to compare the differences, considering a statistically significant p value &lt; 0.05. Results: A total of 149 mPDAC pts were enrolled; TP53 was mutated in 115/149 (77.2%) pts, CDKN2A in 28 (24.3%), CDKN2B in 8 (5.3%), ATM in 6 (4%), TP53BP1 and MDM2 in 2 pts each (1.3%) and ATR in 1 (0.7%). No mutations were found in MDM4, CHEK1 and CHEK2 genes. Overall, 121 (81.2%) pts had at least one mutation in a gene of p53 signaling pathway (p53sigmut) and 28 pts (19.8%) had none (p53sigwt). The most frequent TP53 alterations were single nucleotide variations (SNVs): R175 (10 pts-8.7%), R248 (9 pts-7.8%) and R273 (8 pts-7%); 27 TP53 muts (18.1%) occurred in exon 7, 26 (17.4%) in exon 5, 19 (12.8%) in exon 8 and 13 (8.7%) in exon 4. Median OS (mOS) was 15 months (mos) (CI 95%: 12.8-18.2) in TP53 mutated pts vs 24.3 mos (CI 95%: 17.3-Not reached) in TP53 wt pts, p=0.03. The site of TP53 alteration was correlated with pts’ survival: mOS was 34.9 mos (CI 95%: 31-Nr) in exon 4-mutated pts, 16.9 mos (CI 95%: 11.2-21.2) in exon 7-mut, 13.8 mos (CI 95%: 11.2-17.8) in exon 5-mut and 10.7 mos (CI 95%: 8.2-Nr) in exon 8-mut, p= 0.018. CDKN2A mutations were also associated with survival: mOS was 17.9 mos (CI 95%: 15.9-24.1) in wt pts vs 13.4 (CI 95%: 10.7-22.2) in mutated pts, p= 0.04. CDKN2B, ATM, TP53BP1, MDM2 and ATR mutations were not associated with OS. Overall, patients with at least one mutation in one of the genes of p53 pathway had a mOS of 15 mos (CI 95%: 12.8-18.2) vs 19.6 months (mos) (CI 95%: 17.3-Not reached) in p53sigwt patients. In terms of comutations, TP53 wt pts had a higher frequency of KRAS mutations: 94% vs 64.5%, p&lt;0.001. Conclusions: Our study suggests an important prognostic role of p53 signaling muts in mPDAC pts; wt pts resulted in a longer OS than mutated pts, although some mutations seem to be associated with a longer survival. Further studies are needed to investigate these findings, including an in-depth analysis of structural proteogenomic.

Transcriptome size matters for single-cell RNA-seq normalization and bulk deconvolution

Nature Communications Songjian Lu, Jiyuan Yang, Lei Yan et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56623-1

Abstract The variation of transcriptome size across cell types significantly impacts single-cell RNA sequencing (scRNA-seq) data normalization and bulk RNA-seq cellular deconvolution, yet this intrinsic feature is often overlooked. Here we introduce ReDeconv, a computational algorithm that incorporates transcriptome size into scRNA-seq normalization and bulk deconvolution. ReDeconv introduces a scRNA-seq normalization approach, Count based on Linearized Transcriptome Size (CLTS), which corrects differential expressed genes typically misidentified by standard count per 10 K normalization, as confirmed by orthogonal validations. By maintaining transcriptome size variation, CLTS-normalized scRNA-seq enhances the accuracy of bulk deconvolution. Additionally, ReDeconv mitigates gene length effects and models expression variances, thereby improving deconvolution outcomes, particularly for rare cell types. Evaluated with both synthetic and real datasets, ReDeconv surpasses existing methods in precision. ReDeconv alters the practice and provides a new standard for scRNA-seq analyses and bulk deconvolution. The software packages and a user-friendly web portal are available.

Soft, Modular Power for Composing Robots with Embodied Energy

Advanced Materials Chong‐Chan Kim, Anunth Rao Ramaswami, Robert F. Shepherd Feb 01, 2025 DOI: 10.1002/adma.202414872

Abstract The adaptable, modular structure of muscles, combined with their confluent energy storage allows for numerous architectures found in nature: trunks, tongues, and tentacles to name some more complex ones. To provide an artificial analog to this biological soft muscle, a self‐powered, soft hydrostat actuator is presented. As an example of how to use these modules, a worm robot is assembled where the near totality of the body stores electrochemical potential. The robot exhibits an extremely high system energy density (51.3 J g −1 ), using a redox flow battery motif, with a long theoretical operational range of more than 100 m on a single charge. The innovation lies in the battery pouch, fabricated with a dry‐adhesion method, automatically bonding Nafion separators to a silicone‐urethane copolymer body. These pouches contain anolyte within a hydrostat pod filled with catholyte, increasing current density per pod. Each pod has a motor and tendon actuator for radial compression and expansion. By linking these self‐contained pods in series, the robot worm is created that automatically navigates an enclosed, curved path. This high‐capacity soft worm also climbs up and down a vertical pipe, using a two‐anchor crawling gait, with an extra payload equivalent to 1.5 times its body weight.

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review.

Journal of Clinical Oncology FNU Anamika, Akshit Chitkara, Marciano Figueroa et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.528

528 Background: Liver cancer continues to be a significant public health concern, particularly among high-risk groups such as individuals with hepatitis infections, alcohol use disorders, and metabolic diseases. While liver cancer disparities have been well-documented among racial and ethnic minority groups, emerging research highlights significant health inequities within the LGBTQ community, including higher rates of risk factors and limited access to screening and care. This literature review aims to assess the extent of liver cancer disparities within the LGBTQ community and identify gaps in prevention, screening, and treatment. Methods: We performed a systematic search across PubMed, Scopus, and Google Scholar for peer-reviewed studies published between 2000 and 2024. The inclusion criteria focused on studies addressing liver cancer risk, prevalence, or outcomes in LGBTQ populations. Data on key liver cancer risk factors such as hepatitis B and C prevalence, alcohol use, obesity, and access to healthcare services were extracted and synthesized. Additionally, we reviewed public health reports and clinical guidelines relevant to LGBTQ health disparities. Results: The review identified significant disparities in liver cancer incidence and mortality among LGBTQ individuals. Hepatitis B infection rates were about 1.5 times higher, and hepatitis C rates up to 1.7 times higher among LGBTQ populations, particularly among gay and bisexual men. Alcohol use disorder was about 30-40% more prevalent in LGBTQ individuals, which further increases the risk of liver cancer. Screening for liver cancer in LGBTQ populations is underutilized, with rates approximately 20% lower than the general population. There were reported delays in diagnosis in LGBTQ community due to stigma, discrimination, and lack of culturally competent healthcare services. While some interventions targeting LGBTQ health have shown promise, the overall lack of targeted liver cancer prevention and treatment strategies remains a significant barrier. Conclusions: LGBTQ individuals face increased liver cancer risk due to a higher prevalence of key risk factors and inadequate healthcare access. Current screening and preventive strategies are insufficient for addressing these disparities. Targeted interventions, including enhanced screening efforts, hepatitis vaccination and treatment programs, and the development of LGBTQ-specific healthcare protocols, are needed to reduce the liver cancer burden in this underserved population. Policymakers and healthcare providers must address the unique needs of LGBTQ individuals to achieve equitable cancer outcomes. Prevalence of liver cancer risk factors in LGBTQ vs. general population. Risk Factor LGBTQ Population (%) General Population (%) Hepatitis B Infection 15 10 Hepatitis C Infection 18 12 Alcohol Use Disorder 25 16 Metabolic Syndrome 22 18 Screening Rate 40 60

AGITG SPAR: A randomized, placebo-controlled, phase II trial of simvastatin in addition to neoadjuvant chemotherapy and radiation for rectal cancer.

Journal of Clinical Oncology Michael Jameson, Kirsten Gormly, David Espinoza et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.141

141 Background: Retrospective clinical studies and preclinical studies demonstrated that statin use during preoperative (chemo)radiation (pCRT) for rectal cancer is associated with improved survival, response, and toxicity. Tumor regression following pCRT has strong prognostic significance and can be assessed using MRI-based tumor regression grading (mrTRG), including with non-operative management. SPAR was designed to prospectively evaluate the benefits of adding simvastatin (SIM) to pCRT on tumor regression and gastrointestinal (GI) adverse events (AE). Methods: SPAR is a double-blind randomized phase 2 trial investigating SIM/placebo (PBO) in addition to long-course fluoropyrimidine-based pCRT for rectal adenocarcinoma. Stratification included trial site, clinical T stage (&lt;4 vs 4), clinical N stage (&lt;2 vs 2), either mesorectal fascia involvement (MRFI) or extramural venous invasion (EMVI) on MRI (yes vs no), and total neoadjuvant therapy (TNT): induction vs consolidation chemotherapy vs none. Study treatment was SIM 40mg/PBO daily for 90 days, starting 1 week prior to pCRT; recent statin use was excluded. Pelvic MRI was repeated 6-8 weeks after pCRT to determine mrTRG. An amendment in January 2022 allowed TNT with either induction or consolidation chemotherapy; the timing of post-pCRT MRI remained unchanged. The design was amended to open-label due to PBO supply issues. Primary objective: rate of centrally assessed grade 1-2 mrTRG. Secondary objectives include centrally assessed favorable pathologic TRG (pathTRG), safety and cancer outcomes. Analysis was by intention-to-treat. Results: Between April 2018 - November 2023, 135 of 222 planned participants from 17 sites in Australia and New Zealand were randomized (68 SIM; 67 no SIM). Recruitment was hampered by the COVID-19 pandemic and adoption of TNT as standard care before the protocol amendment. Participant characteristics: median age 59 years; 85 (63%) males; 118 (87%) T2-3 disease, 80 (59%) N0-1 disease; 55 (41%) MRFI or EMVI; 25 (19%) had TNT. Rates of grades 1-2 mrTRG with SIM vs no SIM were 38.5% and 29.7% (X 2 = 1.09, p = 0.30), respectively. There was no significant difference in rates of &gt; grade 2 GI and non-GI AE. Four serious AE were recorded, none related to study treatment. Median follow-up was 3.2 years. 3-year local recurrence rates (LRR) were low: 1 (2.2%) and 3 (5.5%) with SIM vs no SIM, respectively (HR: 0.29, 95% CI: 0.03 to 2.67, p = 0.26). 3-year disease-free survival (DFS) with SIM vs no SIM was 84% and 72%, respectively (HR 0.48; 95% CI: 0.21–1.08, p = 0.07). Conclusions: The rates of favorable mrTRG, 3-year LRR and DFS were numerically better with the addition of SIM to pCRT, though the differences were not statistically significant. SIM was well tolerated. Interpretation is limited by reduced sample size and statistical power. PathTRG and other key outcomes will be presented at the meeting. Clinical trial information: ACTRN12617001087347 .

Effects of the delay of surgery in localized rectal cancer.

Journal of Clinical Oncology Thiago do Amaral Miranda, Clara Braga dos Santos Azevedo, Eronides Salustiano Batalha Filho et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.63

63 Background: The treatment landscape for localized rectal cancer has evolved significantly in recent years, with long-course neoadjuvant chemoradiation (CRT) and total neoadjuvant therapy (TNT) emerging as the primary options. However, the optimal timing of surgery remains an important clinical question, particularly in resource-limited settings where surgical delays can occur. Data from previous studies have shown conflicting results. This retrospective study aimed to assess the impact of delaying surgery beyond the longer interval used in previous studies, focusing on its effects on Pathologic Complete Response (pCR), DFS, and OS. Methods: We conducted a retrospective cohort study using electronic medical records from three centers in Brazil between the years 2013-2024. The study included 236 patients with localized rectal cancer treated with neoadjuvant CRT and/or chemotherapy. Patients were divided into two pre-specified groups based on the interval between the end of neoadjuvant therapy and surgery: ≤11 weeks and &gt;11 weeks. The primary endpoint was DFS. Secondary endpoints were pCR rates, and OS. Descriptive statistics were used for population analysis, while the Kaplan-Meier method estimated DFS and OS, with comparisons made using the log-rank test. A Cox proportional-hazards model was used to estimate hazard ratios and 95% confidence intervals. Results: The median age of the study population was 62 years, with males comprising 56.4% of the sample. The majority of the sample consisted of stage III patients, making up 72.2%, followed by stage II patients at 25.8%, and stage I patients at 1.9%. Most patients (77.8%) had surgery more than 11 weeks after completing neoadjuvant therapy, with a median time to surgery of 16 weeks. The pCR rates did not significantly differ between the two groups (29% for ≤11 weeks vs. 21.5% for &gt;11 weeks; p = 0.271). After a median follow-up of 30 months, the median DFS was not reached, and there was no significant difference between the groups (HR: 0.86; 95% CI: 0.48-1.5; p = 0.63). Similarly, the median OS was not reached, and no difference was observed between the groups (HR: 0.85; 95% CI: 0.47-1.54; p = 0.88). Conclusions: Delaying surgery beyond 11 weeks did not result in greater tumor downstaging in patients with localized rectal cancer. Furthermore, DFS and OS were not significantly impacted by extended intervals between neoadjuvant therapy and surgery.

Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy

Nature Communications A. Contreras-Sanz, G. L. Negri, M. J. Reike et al. Feb 01, 2025 DOI: 10.1038/s41467-024-55665-1

Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.

Journal of Clinical Oncology Arup Ganguly, Ruchir Paladiya, Sushrut Ingawale et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.208

208 Background: The use of total neoadjuvant therapy is now standard of care and is favored when treating locally advanced rectal cancer but its treatment is seldom studied in an underserved population. Methods: A retrospective study was conducted on patients with Stage II and III locally advanced colorectal cancer treated with either total neoadjuvant therapy (TNT) followed by resection or conventional therapy (CT) with chemoradiation followed by surgery, with or without adjuvant treatment afterwards. Patients completed treatment between 2015 and 2023 at the Hartford Hospital Helen and Harry Gray Cancer Center at Hartford, Connecticut. Data collected included demographics, type of treatment, tumor location (high vs mid vs low) and pathological response to treatment spread out among the two groups. Propensity score matching was used to minimize baseline differences between the two groups, adjusted for age, gender, ethnicity and tumor location and Fisher’s exact test was performed to then check for significance. Results: Out of the 133 patients analyzed, 90 underwent TNT, and 43 received CT. The average age at diagnosis was 57.5 years (SD: 11.15). In the TNT group, 79 patients (87.7%) achieved either a partial or complete response (PCR), while 11 patients (12.3%) had No response (NR). Tumor locations in the TNT group were distributed as follows: 13.4% (n=12) had high tumors, 34.4% (n=31) had mid tumors, and 52.2% (n=47) had low tumors. In the CT group, 31 patients (72.9%) achieved PCR, while 12 patients (27.9%) had NR. Tumor locations in the CT group were distributed as follows: 9.3% (n=4) had high tumors, 51.2% (n=22) had mid tumors, and 39.5% (n=17) had low tumors. After propensity score matching and adjusting for demographic covariates, the TNT group demonstrated a higher proportion of responders compared to the CT group (p=0.048). Furthermore, 40% (n=36) of patients in the TNT group achieved a complete response, compared to 32% (n=14) in the CT group. Partial response rates were 39.5% (n=17) in the TNT group and 47.8% (n=43) in the CT group. Conclusions: TNT demonstrated superior pathological response rates compared to CT, which supports its growing role in the management of locally advanced rectal cancer even in this underserved population.

Young onset gastrointestinal cancer: A needs analysis.

Journal of Clinical Oncology Nicola Keohane, John V Reynolds, Emily Harrold et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.383

383 Background: The global incidence of Young Onset ( YO) cancers diagnosed in adults under 50 years, is increasing for unknown reasons. YO Gastrointestinal (GI) cancers, which account for approximately 27% of newly diagnosed cancer cases and 37% of cancer deaths present distinct challenges in areas including sexual health, finance, career and family. We assessed the holistic needs of these patients through a mixed methods approach. Methods: A single institution needs analysis study was undertaken in YO GI patients diagnosed 2014-2024 through an anonymous survey and Focus Group Discussions (FGD). The surveys asked about their experiences of sexual health and function, psychosocial concerns, financial concerns, career developments and when in their cancer journey would they prefer to speak to a health care professional about these. FGD's used nominal group technique to deepen the analysis. Results: 88 participants responded via survey and 10 participated in a FGD. The average age at diagnosis was 43 years. 80% of participants reported they would have benefitted from a conversation about fertility, sexual health/function (82%) and financial supports (98%) at diagnosis. 93% of patients were out of work during cancer treatment with average length of time &gt; 1 year. Conclusions: This needs analysis highlights the importance of specialised clinical pathways for young onset GI cancer patients focusing on these unique and complex needs. Financial supports, conversations regarding sexual health/function, fertility preservation and psychosocial support are critical areas requiring structured intervention. 2014-2024 young onset SJH. UGI ( N=233) Colorectal (N=275) Clinical Stage at diagnosis Oeso Stage 4 = 39% Gastric stage 4 = 26% Stage 3= 46% Stage 4 = 20% Treatment intent % Radical =54% Palliative =38% Radical/Palliative = 8% Radical =75% Palliative 25% Mortality rate 66% 25% GI Survey results ( N=236) Support offered Y/N Preferred timing of support Sexual health/ function No=85% Yes =15% 82% At diagnosis Financial support No=95%Yes= 5% 98% At diagnosis Fertility preservation No = 65% Yes=35% 80% At diagnosis

Impact of race on end-of-life care among patients with esophageal cancer.

Journal of Clinical Oncology Suriya Baskar, Chaula Desai, Udhayvir Singh Grewal Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.337

337 Background: Esophageal cancer is an aggressive malignancy with rising incidence globally. Patients with advanced esophageal cancer suffer from a heavy burden of a wide array of symptoms including dysphagia and cachexia/anorexia, necessitating the need for focused symptom management and palliative care. Studies focused on other cancer types have shown that Black patients are more likely to receive aggressive care at end-of-life (EOL) and suffer from a decline in quality of life. We sought to investigate racial differences in EOL care among patients with advanced esophageal cancer in the US. Methods: The National Inpatient Sample (NIS) was queried to identify all hospitalizations with esophageal cancer utilizing ICD-10 codes C15x from 2016 to 2020. Hospitalizations of White and Black patients with documented inpatient mortality events were then extracted. Demographic and clinical data were analyzed using chi squared tests, independent sample t-tests, and binary logistic regression (adjusted for age, gender, and Charlson comorbidity index or CCI). Adjusted Odds ratios (aOR) are presented with 95% Confidence intervals (CI). Results: A total of 15,130 patients with esophageal cancer were included, of which 13,345 (88.2%) were White and 1785 (11.8%) were Black. Hospitalizations with White patients recorded higher age, more males, and higher comorbidities per CCI. Hospitalizations with Black patients had longer lengths of stay on average, higher total hospital charges, and significantly less likely to have a Do Not Resuscitate (DNR) code status (aOR 0.81, 0.74-0.9 95% CI). Rates of inpatient palliative care consultation at EOL were significantly lower among Black patients (aOR=0.53, 0.48-0.58 95% CI). Black patients were more likely to receive aggressive intervention at EOL demonstrated by rates of blood transfusion (aOR 1.9, 1.6-2.1 95% CI), mechanical ventilation (aOR 1.7, 1.5-1.8 95% CI), and vasopressor usage (aOR 1.4, 1.2-1.6 95% CI). Conclusions: We present a large retrospective analysis demonstrating significant racial disparities in EOL care amongst hospitalized patients with esophageal cancer. Black patients had longer lengths of stay, lower rates of palliative care consultation and DNR code status, and higher rates of aggressive interventions at EOL. These findings may have implications for improving health care decision making for EOL care amongst minority patients with esophageal cancer. WhiteN=13345 BlackN=1785 p-value Age (in years) 68.24±10.67 65.12±10.36 &lt;.001 CCI 9.4±3.3 8.6±3.9 &lt;.001 Mean length of stay (days) 7.5±11.3 10.4±22.8 &lt;.001 Total Cost (In thousands of dollars) 108.6±231.0 141.9±388.5 &lt;.001 Palliative Adjusted OR 60.9% 45.1% .53 (.48 - .58) &lt;.001 DNR Adjusted OR 63.8% 58.0% .81 (.74 - .90) &lt;.001 Blood transfusion Adjusted OR 13.0% 23.0% 1.9 (1.6-2.1) &lt;.001 Mechanical ventilation Adjusted OR 31.4% 45.9% 1.7 (1.5-1.8) &lt;.001 Vasopressor Adjusted OR 7.8% 10.6% 1.4 (1.2-1.6) &lt;.001

The role of viral interaction in household transmission of symptomatic influenza and respiratory syncytial virus

Nature Communications Jessica C. Ibiebele, Elie-Tino Godonou, Amy P. Callear et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56285-z